354P - The Prognostic role Of Age In Salvage Re-irridiation Applied Patients With Recurrent Glioblastoma: A Meta-analysis

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Central Nervous System Malignancies
Surgery and/or Radiotherapy of Cancer
Presenter Ece Dereağzı
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors E. Dereağzı1, V. Kaya2, G. Yazıcı3, M. Yildirim4
  • 1Faculty Of Health Sciences, İstanbul Bilgi University, 34070 - İstanbul/TR
  • 2Department Of Radiation Oncology, Medstar Antalya Hospital, 07000 - Antalya/TR
  • 3Department Of Radiation Oncology, Hacettepe University School of Medicine, Ankara/TR
  • 4İnternal Medicine, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR



Glioblastoma is the most common primary malignant brain tumor in adults. Despite of postoperative adjuvant therapy, glioblastoma recurs in almost all the patients. After recurrence, chemotherapy, carmustine wafer intended for lesions, usage of anti-VEGF, re-operation, re-irradiation are the existent salvage therapy options. In this meta-analysis, the prognostic role of age in Salvage re-irradiation applied patients with recurrence glioblastoma was analyzed.


PubMed and EBSCOhost databases are searched for malignant glioma, high-grade glioma, recurrence, survival, re-irradiation, re- radiation. Browsing databases was done in English.


1588 patients were included to meta-analysis. Pooled hazard ratio showed that overall survival is correlated with re-operation (HR,1.042; 95% CI, 1.012-1.073; p:0,006). Pooled hazard ratio was calculated by using fixed effect model. The quality determinations of 4 studies were done by using Newcastle-Ottowa Scale. The studies were counted low quality with the score 1-3, average quality with the score 4-6, high quality with the score7-9. Median score of the studies was calculated as 5.


In this meta-analysis, we showed that for re-irradiation treatment, which is a salvage therapy option for recurrent glioblastoma, the age is an important prognostic factor.

Clinical trial identification

Legal entity responsible for the study

Mustafa Yıldırım




All authors have declared no conflicts of interest.